Association of Abatacept With Lower Mortality Risk Compared to Rituximab in Rheumatoid Arthritis–Associated Interstitial Lung Disease: An Emulated Target Trial
Arthritis & Rheumatology · 2026
DOI: 10.1002/art.43332 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Arthritis & Rheumatology, 2026. Verfasst von Po-Cheng Shih und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan. Hauptthemen laut MEDLINE: Abatacept, Rituximab, Lung Diseases, Interstitial, Arthritis, Rheumatoid. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
The optimal treatment strategy for rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) remains uncertain, and direct comparative data between biologics are limited. This study aimed to evaluate the effectiveness and safety of abatacept compared with rituximab in patients with RA‐ILD.
Methods
An emulated target trial was designed using the TriNetX US Collaborative Network database, including patients with RA‐ILD, diagnosed between 2007 and 2024. Propensity score matching was used to balance baseline characteristics between the two treatment groups (abatacept and rituximab). The primary outcome was all‐cause mortality, and secondary outcomes included respiratory events, medical utilization, and infection‐related adverse events. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated to use Cox proportional hazards models.
Results
In total, 1,615 patients per group were identified after matching for analysis. Abatacept was associated with a significantly lower risk of all‐cause mortality compared with rituximab (HR, 0.689; 95% CI, 0.581–0.818) and a reduced risk of mechanical ventilation (HR, 0.698; 95% CI, 0.521–0.934). The subgroup analyses yielded consistent findings. Sensitivity analyses excluding patients with concomitant connective tissue diseases also demonstrated consistent results (mortality: HR, 0.679; 95% CI, 0.570–0.810), reinforcing the robustness of the findings.
Conclusion
Abatacept was associated with a lower risk of mortality compared with rituximab in patients with RA‐ILD. Because clinicians may preferentially reserve abatacept for less aggressive RA‐ILD, residual confounding by indication cannot be excluded; thus, the association should not be interpreted as proof of causality. Prospective randomized trials are needed to confirm whether abatacept confers a true survival advantage. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
- Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan.
- Center for Health Data Science, Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan.
- Department of Health Policy and Management, College of Health Care and Management, Chung Shan Medical University, Taichung, Taiwan.
- Department of Allergy, Immunology and Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan.
- Office of Research and Development, Asia University, Taichung, Taiwan.
ORCID-Profile: Po-Cheng Shih, James Cheng Chung Wei
Zitieren
APA
Shih, P. C., Wang, S. I., & Wei, J. C. C. (2026). Association of Abatacept With Lower Mortality Risk Compared to Rituximab in Rheumatoid Arthritis–Associated Interstitial Lung Disease: An Emulated Target Trial. Arthritis & Rheumatology. https://doi.org/10.1002/art.43332
Vancouver
Shih PC, Wang SI, Wei JCC. Association of Abatacept With Lower Mortality Risk Compared to Rituximab in Rheumatoid Arthritis–Associated Interstitial Lung Disease: An Emulated Target Trial. Arthritis & Rheumatology. 2026. doi:10.1002/art.43332
BibTeX
@article{Shih2026,
author = {Shih, Po-Cheng and Wang, Shiow-Ing and Wei, James Cheng Chung},
title = {Association of Abatacept With Lower Mortality Risk Compared to Rituximab in Rheumatoid Arthritis–Associated Interstitial Lung Disease: An Emulated Target Trial},
journal = {Arthritis & Rheumatology},
year = {2026},
doi = {10.1002/art.43332}
}
EUVIMED